Objective:To observe the effect of betamethasone combined with ropivacaine on postoperative analgesia and sleep depth in patients undergoing laparoscopic cholecystectomy.Methods:A total of 150 patients undergoing laparoscopic cholecystectomy treated in the Hangzhou Traditional Chinese Medicine Hospital from October 2021 to December 2022 were selected as the study objects and divided into group A, group B and group C, with 50 cases in each group. Groups A and B were treated with ropivacaine and betamethasone at different doses (5 mg, 2.5 mg), while group C was treated with ropivacaine only. The perioperative period indexes of the three groups were compared. Pain degree at 4, 8, 12, 24 and 48 h after surgery and Pittsburgh Sleep index (PSQI) scores at 1 day before surgery, 1 day and 2 days after surgery were compared among the three groups.Results:There were no significant differences in operation time, anesthesia time, postoperative exhaust time and hospital stay, and the dosage of fentanyl and propofol among the three groups (all P>0.05). The Visual Analogue Scale (VAS) scores of group A and group B at 4, 8, 12, 24 and 48 h after surgery were significantly lower than those of the group C (all P<0.05), and the VAS scores of group A at 12, 24 and 48 h after surgery were significantly lower than those of the group B (all P<0.05). There was no significant difference in PSQI scores 1 day before surgery among the three groups (all P>0.05). The PSQI scores of the group A and the group B 1 and 2 days after surgery were significantly lower than those of the group C (all P<0.05), and the PSQI scores of the group A 2 days after surgery were significantly lower than those of the group B, with statistical significance ( P<0.05). There was no significant difference in the incidence of adverse reactions between the group A and the group B and the group C (all P>0.05). Conclusions:Betamethasone combined with ropivacaine can improve postoperative analgesia and sleep quality in patients undergoing laparoscopic cholecystectomy.

Objective:To observe the effect of betamethasone combined with ropivacaine on postoperative analgesia and sleep depth in patients undergoing laparoscopic cholecystectomy.Methods:A total of 150 patients undergoing laparoscopic cholecystectomy treated in the Hangzhou Traditional Chinese Medicine Hospital from October 2021 to December 2022 were selected as the study objects and divided into group A, group B and group C, with 50 cases in each group. Groups A and B were treated with ropivacaine and betamethasone at different doses (5 mg, 2.5 mg), while group C was treated with ropivacaine only. The perioperative period indexes of the three groups were compared. Pain degree at 4, 8, 12, 24 and 48 h after surgery and Pittsburgh Sleep index (PSQI) scores at 1 day before surgery, 1 day and 2 days after surgery were compared among the three groups.Results:There were no significant differences in operation time, anesthesia time, postoperative exhaust time and hospital stay, and the dosage of fentanyl and propofol among the three groups (all P>0.05). The Visual Analogue Scale (VAS) scores of group A and group B at 4, 8, 12, 24 and 48 h after surgery were significantly lower than those of the group C (all P<0.05), and the VAS scores of group A at 12, 24 and 48 h after surgery were significantly lower than those of the group B (all P<0.05). There was no significant difference in PSQI scores 1 day before surgery among the three groups (all P>0.05). The PSQI scores of the group A and the group B 1 and 2 days after surgery were significantly lower than those of the group C (all P<0.05), and the PSQI scores of the group A 2 days after surgery were significantly lower than those of the group B, with statistical significance ( P<0.05). There was no significant difference in the incidence of adverse reactions between the group A and the group B and the group C (all P>0.05). Conclusions:Betamethasone combined with ropivacaine can improve postoperative analgesia and sleep quality in patients undergoing laparoscopic cholecystectomy.

This study examined the synergetic effect of class IA Phosphoinositide 3-kinases catalytic subunit p110β knockdown in conjunction with oxaliplatin treatment on colon cancer cells. Down-regulation of p110β by siRNA interference and oxaliplatin treatment were applied in colon cancer cell lines HT29, SW620 and HCT116. MTT assay was used to measure the inhibitory effect of p110β knockdown on the proliferation of colon cancer cell lines. SubG1 assay and Annexin-V FITC/PI double-labeling cytometry were applied to detect cell apoptosis. And cell cycle was evaluated by using PI staining and flow cytometry. The expression of caspase 3, cleaved PARP, p-Akt, T-Akt and p110β was determined by western blotting. The results suggested that down-regulation of p110β expression by siRNA obviously reduced cell number via accumulation in G(0)-G(1) phase of the cell cycle in the absence of notablely increased apoptosis in colon cancer cell lines HT29 and SW620 (S phase arrest in HCT116). Moreover, inhibition of p110β expression increased oxaliplatin-induced cell apoptosis and cell cycle arrest in HT29, HCT116 and SW620 cell lines. In addition, increases of cleaved caspase-3 and cleaved PARP induced by oxaliplatin treatment were determined by immunoblotting in p110β knockdown group compared with normal control group and wild-type group. It is concluded that down-regulated expression of p110β could inhibit colon cancer cells proliferation and result in increased chemosensitivity of colorectal cancer cells to oxaliplatin through augmentation of oxaliplatin-induced cell apoptosis and cell cycle arrest.

This study examined the synergetic effect of class IA Phosphoinositide 3-kinases catalytic subunit p110β knockdown in conjunction with oxaliplatin treatment on colon cancer cells.Down-regulation of p110β by siRA interference and oxaliplatin treatment were applied in colon cancer cell lines HT29,SW620 and HCT116.MTT assay was used to measure the inhibitory effect of p110 knockdown on the proliferation of colon cancer cell lines.SubG1 assay and Annexin-V FITC/PI double-labeling cytometry were applied to detect cell apoptosis.And cell cycle was evaluated by using PI staining and flow cytometry.The expression of caspase 3,cleaved PARP,p-Akt,T-Akt and p 110β was dctermined by western blotting.The results suggested that down-regulation of p110β expression by siRNA obviously reduced cell number via accumulation in G0-G1 phase of the cell cycle in the absence of notablely increased apoptosis in colon cancer cell lines HT29 and SW620 (S phase arrest in -HCT116).Moreover,inhibition of p110β expression increased oxaliplatin-induced cell apoptosis and cell cycle arrest in HT29,HCT116 and SW620 cell lines.In addition,increases of cleaved caspase-3 and cleaved PARP induced by oxaliplatin treatment were determined by immunoblotting in p110β knockdown group compared with normal control group and wild-type group.It is concluded that down-regulated expression of p110β could inhibit colon cancer cells proliferation and result in increased chemosensitivity of colorectal cancer cells to oxaliplatin through augmentation of oxaliplatin-induced cell apoptosis and cell cycle arrest.

Objective:To investigate the effect of retinoid-interferon-induced mortality (GRIM-19) gene on the apoptosis of colon cancer. Methods: A GRIM-19 eukaryotic expression vector (pCMV-Flag-GRIM-19) was constructed and transfected into SW480 cells. Expressions of GRIM-19 and apoptosis-related proteins were detected by Western blotting analysis. Apoptosis of SW480 cells was measured by Annexin-V/PI assay and mitochondrial membrane potential JC-1 staining. Results: The GRIM-19 eukaryotic expression vector pCMV-Flag-GRIM-19 was successfully constructed. Expression of GRIM-19 in SW480 cells was up-regulated and that of apoptosis-related protein Bcl-xl was down-regulated after transfection with pCMV-Flag-GRIM-19. Apoptosis rate was (7.7±1.39)% in SW480 cells transfected with pCMV-Flag empty vector and (15.0 ± 2.52)% in pCMV-Flag-GRIM-19 transfected cells (P<0.05). Mitochondrial membrane potential was decreased in (7.5±2.09)% of pCMV-Flag transfected cells and (17.5±3.07)% of pCMV-Flag-GRIM-19 transfected cells (P<0.05). Conclusion: In vitro GRIM-19 transfection can effectively induce apoptosis of colon cancer SW480 cells.

In order to examine the effect of GRIM 19 on colon cancer cell SW480, the recombinant adenovirus carrying GRIM19 gene was constructed and transfected into SW480 cells. GRIMI9 cDNA was amplified by PCR with the template pcxn2-GRlMl9 and cloned into the shuttle plasmid pAdTrack-CMV. The plasmid pAdTrack-CMV-GRIM19 was linearized by PmeI and homologously recombined with bone plasmid pAdEasy-1 in BJ5183, followed by identification by enzyme diges- tion. After transfection of linearized pAd-GRIM19 with PacI into HEK293 cells, Ad-GRIMI9 was obtained and amplified by 3 circles. SW480 cells were infected with Ad-GRIM19. The apoptosis rate was detected by flow cytometry. Agarose electrophoresis revealed the bands of recombinant plasmids identified by enzyme digestion were in the right range corresponding with expectation. Under the fluorescent microscopy, the package of Ad-GRIM19 in HEK293 cells and the expression of Ad-GRIM19 in SW480 cells were observed. The transfection of Ad-GRIM19 into SW480 cells in-creased the apoptosis rate of SW480 cells as compared with controls. It was concluded that Ad-GRIM19 was successfully constructed and the overexpression of GRIM19 in colon cancer cell lines could promote the apoptotic cell death.